New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and MET mutations, ALK, ROS1, NTRK and RET translocations, and PD-L1 expression in these patients is considered essential....

Descripción completa

Detalles Bibliográficos
Autores principales: Isla, Dolores, Lozano, Maria D., Paz-Ares, Luis, Salas, Clara, de Castro, Javier, Conde, Esther, Felip, Enriqueta, Gómez-Román, Javier, Garrido, Pilar, Enguita, Ana Belén
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119050/
https://www.ncbi.nlm.nih.gov/pubmed/36571695
http://dx.doi.org/10.1007/s12094-022-03046-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119050/
https://www.ncbi.nlm.nih.gov/pubmed/36571695
http://dx.doi.org/10.1007/s12094-022-03046-9

Ejemplares similares